Back to news

Chips & deep tech ยท Article

Samsung Biologics Goes Pure CDMO as Celltrion Signs 400 Billion Won Production Deal

๋น„์ฆˆ์›Œ์น˜ ยท

At a glance

Samsung Biologics split off its biosimilar business and now focuses purely on contract manufacturing, which has changed alliances in the bio industry. Celltrion, a long-time rival, signed a contract worth over 400 billion won with Samsung Biologics for drug production.

Key points

Why it matters

It shows that rival drugmakers can now cooperate by splitting development and production roles, which could change how the bio industry competes.

Original source

๋ฐ˜๋„์ฒด ์—…๊ณ„์ฒ˜๋Ÿผโ€ฆ๋ฐ”์ด์˜ค ํŒ๋„ '์ˆœ์ˆ˜ CDMO'๊ฐ€ ๋ฐ”๊ฟจ๋‹ค

๋น„์ฆˆ์›Œ์น˜ ยท Nov 20, 07:40 KST

Read on ๋น„์ฆˆ์›Œ์น˜ โ†—

AI summarized the original article. Check the original for accuracy. Copyright belongs to ๋น„์ฆˆ์›Œ์น˜.

Chips & deep tech